Hypoglycemia - Pipeline Review, H1 2019

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hypoglycemia - Pipeline Review, H1 2019, provides an overview of the Hypoglycemia (Metabolic Disorders) pipeline landscape.

Hypoglycemia is a condition characterized by an abnormally low level of blood sugar (glucose). Symptoms of hypoglycemia include tachycardia, anxiety, shaking, and irritability, feelings of hunger, weakness, tiredness, dizziness, headache, confusion, and trouble concentrating. Risk factors include drug or alcohol consumption, older age, longer duration of diabetes, renal disease, peripheral neuropathy, obesity and cognitive dysfunction.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hypoglycemia - Pipeline Review, H1 2019, provides comprehensive information on the therapeutics under development for Hypoglycemia (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hypoglycemia (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hypoglycemia and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Unknown stages are 2, 1, 2, 5, 4 and 2 respectively.

Hypoglycemia (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Hypoglycemia (Metabolic Disorders).

- The pipeline guide reviews pipeline therapeutics for Hypoglycemia (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

- The pipeline guide reviews key companies involved in Hypoglycemia (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

- The pipeline guide evaluates Hypoglycemia (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

- The pipeline guide reviews latest news related to pipeline therapeutics for Hypoglycemia (Metabolic Disorders)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

- Find and recognize significant and varied types of therapeutics under development for Hypoglycemia (Metabolic Disorders).

- Classify potential new clients or partners in the target demographic.

- Develop tactical initiatives by understanding the focus areas of leading companies.

- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

- Formulate corrective measures for pipeline projects by understanding Hypoglycemia (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.

- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hypoglycemia - Overview
Hypoglycemia - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Products under Development by Companies
Hypoglycemia - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Hypoglycemia - Companies Involved in Therapeutics Development
Adocia SAS
AMAG Pharmaceuticals Inc
Arecor Ltd
Eiger BioPharmaceuticals Inc
Eli Lilly and Co
LATITUDE Pharmaceuticals Inc
Novartis AG
Rezolute Inc
Sosei Heptares
Therakind Ltd
USV Pvt Ltd
XERIS Pharmaceuticals Inc
Zealand Pharma AS
Zucara Therapeutics Inc
Hypoglycemia - Drug Profiles
avexitide acetate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
dasiglucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug for Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
glucagon biosimilar - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3143753 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-3185643 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LY-900018 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
pasireotide - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RZ-358 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize GLP-1 Receptor for Congenital Hyperinsulinism and Hypoglycemia - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ZT-01 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Hypoglycemia - Dormant Projects
Hypoglycemia - Discontinued Products
Hypoglycemia - Product Development Milestones
Featured News & Press Releases
Mar 25, 2019: Eiger BioPharmaceuticals Announces Oral Presentation of Phase 2 PREVENT Study Results of Avexitide in Post-Bariatric Hypoglycemia at Endocrine Society Meeting (ENDO) 2019
Mar 25, 2019: Xeris Pharmaceuticals presents new clinical and economic impact data on its developmental ready-to-use Glucagon
Mar 14, 2019: Xeris Pharmaceuticals doses first patient in phase 2 trial evaluating its ready-to-use glucagon to address exercise-induced hypoglycemia
Mar 07, 2019: Zealand Pharma begins dosing in Phase III trial for CHI
Feb 13, 2019: XOMA receives $5.5 Million payment from Rezolute
Feb 12, 2019: Adocia to present new clinical data on BioChaperone Glucagon at the 12th International Conference on Advanced Technologies & Treatments for Diabetes (ATTD 2019)
Feb 04, 2019: Eiger BioPharmaceuticals announces oral presentation of phase 2 PREVENT study of avexitide in post-bariatric hypoglycemia (PBH) at upcoming Endocrine Society (ENDO) Meeting 2019 in New Orleans
Jan 17, 2019: LATITUDE Pharmaceuticals receives notice of allowance for U.S. Patent Covering Stabilized Aqueous Glucagon Formulations
Dec 20, 2018: European medicines agency grants orphan drug designation for Xeris’ investigational ready to use glucagon for the treatment of Non-Insulinoma Pancreatogenous Hypoglycaemia Syndrome (NIPHS)
Dec 11, 2018: Eiger BioPharmaceuticals provides update on Avexitide at 2018 R&D Day
Nov 12, 2018: Xeris Pharmaceuticals releases additional phase 3 clinical trial data on its ready-to-use Liquid Glucagon Pen
Oct 23, 2018: Xeris Pharmaceuticals announces FDA acceptance for review of NDA for its ready-to-use Glucagon Rescue Pen
Oct 16, 2018: Eiger BioPharmaceuticals announces positive results in phase 2 PREVENT study of Avexitide targeting GLP-1 in post-bariatric hypoglycemia (PBH)
Sep 27, 2018: Zealand Pharma has initiated the Phase 3 trial with dasiglucagon for treatment of severe hypoglycemia in children
Sep 18, 2018: Zealand Pharma achieves primary and key secondary endpoints in pivotal Phase 3 trial with dasiglucagon for severe hypoglycemia
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer